Compare GSK plc (GSK) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs McCormick & Company, Incorporated — how do they compare? GSK plc trades at $50.35 (market cap $102.60B), while McCormick & Company, Incorporated trades at $53.21 (market cap $14.22B). The key difference: GSK plc is far larger — about 7.2× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| GSK | MKC | |
|---|---|---|
Market Cap | $102.60B | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $72.26 |
52-Week Low | $38.22 | $45.60 |
Enterprise Value | $123.04B | $18.82B |
Dividend Yield | 3.57% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
MKC trades at $53.13, up 0.32% today, with a bullish technical signal and strong profitability metrics including a 21.91% net income margin and 25.7% ROE. Recent Q2 2026 results beat expectations, driven by acquisitions and margin expansion. The pending Unilever Foods merger, expected to close in 2027, dominates news flow and offers transformative growth potential.
The outlook is positive, with a consensus price target of $59.67 implying 12% upside. Key opportunities include merger synergies and sustained dividend growth, while risks involve integration execution and soft consumer volumes. Analysts are mixed but lean bullish on valuation and strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
